PMC6271067 Sikiric P, et al
Limited data support the use of propionyl-L-carnitine for treatment of intermittent claudication in patients with peripheral artery disease, and data do not support its use in the treatment of congestive heart failure
This is why short-half-life secretagogues are favored for studying physiological pulsatile dynamics
Still, it may be relevant to perform pilot studies to address whether the therapy will benefit selected HFrEF cohorts with obesity.
Recognizing red flags before you hand over money for a bulk order can save you thousands of dollars and months of wasted research time
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited